Respiratory News and Research

RSS

Study reveals association between sleep-disordered breathing and Alzheimer's disease

Alzheimer's disease affects millions of people worldwide. As a result of an increase in life expectancy, the number of patients with dementia is expected to increase dramatically. Due to the lack of effective treatments that can slow down or reverse the progression of AD, preventive measures to lower the prevalence rate of AD by means of managing potential or actual risk factors is a reasonable clinical strategy.

9 Oct 2013

FMCNA encourages dialysis patients to get vaccinated against flu

With early cases of seasonal flu already being reported in the U.S., Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is strongly encouraging dialysis patients to get flu shots to protect themselves against this common infectious disease.

9 Oct 2013

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

ProTip SAS, the specialist developer of innovative medical devices for patients suffering from laryngeal malfunction, and Strasbourg University Hospitals today announce that they have successfully completed the first implantation of an artificial larynx in a human patient.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Hypothyroidism linked to COPD exacerbation risk

Research shows that chronic obstructive pulmonary disease patients with hypothyroidism have an elevated exacerbation frequency but, despite this, experience similar quality of life to patients with normal thyroid function.

8 Oct 2013

Hyperglycemia heightens pneumonia risk in pediatric burns patients

Research indicates that hyperglycemia puts pediatric burns patients at increased risk for pneumonia.

8 Oct 2013

Smoking during pregnancy may affect child’s immune system on molecular level

The Leipzig Helmholtz Center for Environmental Research has gained new insights on the influence of tobacco smoke in utero. For the first time, it could be demonstrated with smoking pregnant women and their children, how exposure to tobacco smoke affects the development of human immune system on molecular level.

8 Oct 2013

Eddingpharm Secures Immutep’s Immufact IMP321 For Growing Stable

Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.

7 Oct 2013

Study finds association between heart failure and air pollution

Air pollution increases heart attacks, according to research presented at the Acute Cardiac Care Congress 2013 by Dr Savina Nodari from Brescia, Italy.

7 Oct 2013

Study shows how evolution shaped lungs through successive optimizations of physical parameters

Two French physicists, Bernard Sapoval and Marcel Filoche from -cole Polytechnique in Palaiseau, France, suggest in a study published in EPJ E how evolution has shaped our lungs through successive optimisations of physical parameters such as conservation of energy and speed of delivery.

7 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

5 Oct 2013

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

5 Oct 2013

Asthma alert in very physically active

Research from Sweden shows that while people with asthma are as likely to be mildly active or inactive as people without, there is a strong relationship between vigorous physical activity and the respiratory condition.

3 Oct 2013

Gas transfer excels in predicting mortality in COPD

Researchers say that measuring gas transfer is the most effective way to predict mortality in chronic obstructive pulmonary disease, after finding that it outperformed both spirometry and plethysmography for the purpose.

3 Oct 2013

'Early-term' babies more likely to experience higher risk for adverse health outcomes

Babies considered "early-term," born at 37 or 38 weeks after a mother's last menstrual period, may look as healthy as full-term babies born at 39-41 weeks, but a new study published by University at Buffalo physicians in JAMA Pediatrics has found that many of them are not.

3 Oct 2013

Researchers to develop nerve agent antidotes that can be used during chemical warfare

Ever since World War II, nerve agents have been a concern in modern warfare and up until now, the only antidotes available acted after the agents damaged the nervous system.

3 Oct 2013

Respiratory News and Research

Study reveals association between sleep-disordered breathing and Alzheimer's disease

FMCNA encourages dialysis patients to get vaccinated against flu

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Hypothyroidism linked to COPD exacerbation risk

Hyperglycemia heightens pneumonia risk in pediatric burns patients

Smoking during pregnancy may affect child’s immune system on molecular level

Eddingpharm Secures Immutep’s Immufact IMP321 For Growing Stable

Study finds association between heart failure and air pollution

Study shows how evolution shaped lungs through successive optimizations of physical parameters

Newly discovered compound could be developed as antifungal drug to treat fungal infections

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Asthma alert in very physically active

Gas transfer excels in predicting mortality in COPD

'Early-term' babies more likely to experience higher risk for adverse health outcomes

Researchers to develop nerve agent antidotes that can be used during chemical warfare

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News